REV-ERB and muscle regeneration
Focus Biomolecules
July 16, 2026
FOCUS on muscle regeneration. A group at Wash. U. recently reported on a compound designated BE2012 in J. Med. Chem. BE2012 was shown to be a
News & Events
Progress on Parkinson’s research
Focus Biomolecules
July 14, 2026
In a paper just out in Redox Biology, the authors show that inhibition of 15-OH-PGDH with SW033291 restores redox homeostasis and confers neuroprotection in Parkinson’s disease.
Visit Focus Biomolecules at ISSCR
Focus Biomolecules
June 25, 2026
Focus Biomolecules will be exhibiting at the annual meeting of the International Society for Stem Cell Research in Montreal, July 8 – 10. Stop by our
Enhancing cancer immunotherapy with asthma drug
Focus Biomolecules
May 28, 2026
FOCUS on Drug Repurposing. Montelukast is a cysteinyl leukotriene receptor (CysLTR1) antagonist currently in use for asthma. In a paper just out in Nature Cancer, a
First PROTAC approved
Focus Biomolecules
May 8, 2026
FOCUS on PROTACs. On May 1st the first PROTAC, a heterobifunctional protein degrader and a new therapeutic modality, was approved by the FDA. Vepdegestrant (Arvinas’ Veppanu)
GSK-3β inhibitor for pancreatic cancer
Focus Biomolecules
April 30, 2026
FOCUS on Pancreatic Cancer. In a paper just out in Nature Medicine, the team at Actuate Therapeutics reported the results of their Phase II trial on